ROSEN, SKILLED INVESTOR COUNSEL, Encourages Hayward Holdings, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – HAYW

NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hayward Holdings, Inc. (NYSE: HAYW) between March 2, 2022 and July 27, 2022, both dates inclusive (the “Class Period”), of the important October 2, 2023 lead plaintiff deadline. SO WHAT: If […]

NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hayward Holdings, Inc. (NYSE: HAYW) between March 2, 2022 and July 27, 2022, both dates inclusive (the “Class Period”), of the important October 2, 2023 lead plaintiff deadline.

SO WHAT: If you purchased Hayward securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Hayward class action, go to https://rosenlegal.com/submit-form/?case_id=12009 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 2, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Hayward Holdings and its management had engaged in a channel-stuffing scheme designed to artificially boost Hayward Holdings’ short-term sales and earnings; (2) Hayward Holdings had flooded its channel partners with inventory that they did not want or need at a level that far outpaced then-existing consumer demand; (3) Hayward Holdings’ channel partners were suffering from an inventory glut as a result of the channel-stuffing scheme that would require a massive de-stocking in the second half of 2022; (4) Hayward Holdings’ channel-stuffing scheme had cannibalized future sales, materially impairing Hayward Holdings’ ability to sell to its customers; (5) the demand for pool equipment had slowed down, which, combined with flooding channel partners with more inventory, led to an inventory glut and the need for these channel partners to reduce inventory levels; and (6) as a result of the above, Hayward Holdings’ projected 2022 financial results were not achievable and lacked a reasonable basis in fact. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Hayward class action, go to https://rosenlegal.com/submit-form/?case_id=12009 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8892224

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BTAI

NEW YORK, Aug. 11, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) between December 15, 2021 and June 28, 2023, both dates inclusive (the “Class Period”), of the important September 5, 2023 lead plaintiff deadline. SO WHAT: If you […]

NEW YORK, Aug. 11, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) between December 15, 2021 and June 28, 2023, both dates inclusive (the “Class Period”), of the important September 5, 2023 lead plaintiff deadline.

SO WHAT: If you purchased BioXcel Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the BioXcel Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=17579 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 5, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) BioXcel Therapeutics lacked adequate internal controls over protocol adherence and data integrity; (2) as a result, BioXcel Therapeutics’s principal investigator failed to adhere to the informed consent form approved by the Institutional Review Board (“IRB”); (3) BioXcel Therapeutics’s principal investigator failed to maintain adequate case histories for certain patients whose records were reviewed by the U.S. Food and Drug Administration (“FDA”); (4) BioXcel Therapeutics’s principal investigator fabricated email correspondence with a pharmacovigilance safety vendor that was then provided to the FDA; (5) the foregoing would negatively impact BioXcel Therapeutics’s ability to obtain regulatory approval of BXCL501 (which is purportedly a proprietary, orally dissolving, film formulation of dexmedetomidine, or “Dex”) for the treatment of agitation associated with dementia in patients with probable Alzheimer’s disease; and (6) as a result of the foregoing, defendants’ positive statements about BioXcel Therapeutics’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the BioXcel Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=17579 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8892342

SE SHAREHOLDER ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Sea Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action – SE

NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sea Limited (NYSE: SE) between April 23, 2022 and May 15, 2023, both dates inclusive (the “Class Period”), of the important September 19, 2023 lead plaintiff deadline. SO WHAT: If you purchased […]

NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sea Limited (NYSE: SE) between April 23, 2022 and May 15, 2023, both dates inclusive (the “Class Period”), of the important September 19, 2023 lead plaintiff deadline.

SO WHAT: If you purchased Sea securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Sea class action, go to https://rosenlegal.com/submit-form/?case_id=17863 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 19, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Sea overstated its ability to manage the growth of its user base and loan book while enhancing its profitability; (2) Sea’s expansion to a broader user base and growing loan book rendered the Company significantly more vulnerable to higher credit losses; (3) as a result, the Company was likely to book a significant increase in loan loss reserves; (4) the foregoing was likely to have a significant negative impact on Sea’s earnings; and (5) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Sea class action, go to https://rosenlegal.com/submit-form/?case_id=17863 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8892487

ROSEN, A LONGSTANDING LAW FIRM, Encourages Eos Energy Enterprises, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EOSE, EOSEW

NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Eos Energy Enterprises, Inc. (NASDAQ: EOSE, EOSEW) between May 9, 2022 and July 27, 2023, both dates inclusive (the “Class Period”), of the important October 2, 2023 lead plaintiff deadline. SO WHAT: […]

NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Eos Energy Enterprises, Inc. (NASDAQ: EOSE, EOSEW) between May 9, 2022 and July 27, 2023, both dates inclusive (the “Class Period”), of the important October 2, 2023 lead plaintiff deadline.

SO WHAT: If you purchased Eos securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Eos class action, go to https://rosenlegal.com/submit-form/?case_id=18041 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 2, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Bridgelink Commodities, LLC (“Bridgelink”) is connected to a group whose assets were seized by a creditor and sold in an auction; (2) as such, Bridgelink’s commitment and ability to purchase Eos products was not as secure as Eos had led investors to believe; (3) as such, Eos’s backlog was overstated; (4) such overstatement negatively impacts Eos’s ability to secure a loan from the Department of Energy; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Eos class action, go to https://rosenlegal.com/submit-form/?case_id=18041 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8892241

ROSEN, A RANKED AND LEADING FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – APLS

NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between January 28, 2021 and July 28, 2023, both dates inclusive (the “Class Period”). A class […]

NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between January 28, 2021 and July 28, 2023, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 2, 2023.

SO WHAT: If you purchased Apellis common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Apellis class action, go to https://rosenlegal.com/submit-form/?case_id=17734 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 2, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) SYFOVRE’s (an intravitreal pegcetacoplan injection which is the first and only approved therapy for geographic atrophy (“GA”), a leading cause of blindness) design of clinical trials was insufficient to identify incidents of retinal vasculitis in patients receiving SYFOVRE injections; (2) as a result, the commercial adoption of SYFOVRE was subject to significant, unknown risk factors; and (3) therefore, defendants’ statements about Apellis’ business, operations, and prospects lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Apellis class action, go to https://rosenlegal.com/submit-form/?case_id=17734 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8892303

Document Reveals U.S. Attempt To Remove Former Pakistani PM

The United States had exerted pressure to remove former Pakistani Prime Minister, Imran Khan, in 2022, due to his government’s neutral policy on the Ukraine crisis, the online American magazine “The Intercept” revealed on Wednesday.The magazine said, i…

The United States had exerted pressure to remove former Pakistani Prime Minister, Imran Khan, in 2022, due to his government’s neutral policy on the Ukraine crisis, the online American magazine “The Intercept” revealed on Wednesday.

The magazine said, it obtained a classified Pakistani government cable, about a dialogue between Pakistan’s then-ambassador to the United States, Asad Majeed Khan and U.S. Assistant Secretary of State for South and Central Asian Affairs, Donald Lu, on Mar 7, 2022.

In the cable, Lu expressed his dissatisfaction with the foreign policy of the Pakistani government led by Khan, and asserted that Pakistan would only be forgiven by the United States, if the prime minister is removed through a no-confidence vote in parliament.

“I think if the no-confidence vote against the prime minister succeeds, all will be forgiven in Washington … Otherwise, I think it will be tough going ahead,” said Lu.

According to media reports, on Mar 27, 2022, Khan, then-Pakistani prime minister, spoke publicly about the cable at a political rally in Islamabad, accusing the United States of hatching a conspiracy to overthrow his government. Days later, Khan told reporters that the Pakistani side regarded the U.S. act as blatant interference in Pakistan’s internal affairs.

On Apr 10, 2022, Pakistan’s National Assembly, the lower house of parliament, passed a no-confidence motion against Khan.

On May 9, Khan was arrested by the National Accountability Bureau, under alleged charges of corruption and corrupt practices. On Aug 5, he was sentenced to three years in prison and banned from holding any public office for five years

Source: Nam News Network

Never-Seen-Before Crowd at Passport Offices as Record Pakistanis Want to Leave Country

Passport issuance for individuals traveling abroad remains stable, with a daily influx of 40,000 people visiting passport offices.According to authorities, there has been a significant increase in the number of citizens applying for passports in the p…

Passport issuance for individuals traveling abroad remains stable, with a daily influx of 40,000 people visiting passport offices.

According to authorities, there has been a significant increase in the number of citizens applying for passports in the past few months.

To facilitate international travel, approximately 40,000 individuals are visiting passport offices daily, signaling a heightened demand for this essential travel document.

Officials further elaborate that due to the substantial surge in application data, the passport processing staff is facing certain challenges.

In order to ensure timely delivery of passports to citizens, printing and processing activities are now being conducted on weekends, both Saturdays and Sundays.

This initiative aims to streamline the passport issuance process and cater to the growing needs of individuals seeking to travel abroad. As the volume of passport applications continues to rise, authorities are taking proactive measures to meet the demands of citizens while upholding the efficiency and integrity of the passport issuance system.

Source: Pro Pakistani

Price of Gold in Pakistan Continues Volatile Streak

Gold maintained its volatile streak in Pakistan on Friday with the price of the precious metal dropping after two successive increases.According to the data released by All-Pakistan Sarafa Gems and Jewellers Association (APSGJA), the price of gold (24…

Gold maintained its volatile streak in Pakistan on Friday with the price of the precious metal dropping after two successive increases.

According to the data released by All-Pakistan Sarafa Gems and Jewellers Association (APSGJA), the price of gold (24 carats) dropped by Rs. 400 per tola to Rs. 222,400 while the price of 10 grams decreased by Rs. 343 to close at Rs. 190,672.

Despite avoiding any major changes, the price of gold has remained volatile for the past many ways. In the current week, the price of gold opened the new week with two successive drops which was followed by two successive increases.

Cumulatively, the price of gold has dropped by Rs. 400 per tola in the current week so far. Last week the price of gold had dropped by Rs. 1,900 per tola.

In the international market, spot gold jumped 0.3 percent to $1,917.73 per ounce by 1037 GMT, while the US gold futures were up 0.1 percent to $1,950.20.

Source: Pro Pakistani